Co-Authors
This is a "connection" page, showing publications co-authored by Russell Z. Szmulewitz and Theodore Karrison.
Connection Strength
0.755
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
Score: 0.209
-
Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061.
Score: 0.163
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.158
-
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103.
Score: 0.084
-
A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
Score: 0.049
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
Score: 0.035
-
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
Score: 0.033
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.025